High-dose methotrexate vs. Capizzi methotrexate for the treatment of childhood T-cell acute lymphoblastic leukemia

Area of Science:

• Pediatric Oncology
• Hematology
• Leukemia Research

Background:

• T-cell acute lymphoblastic leukemia (T-ALL) is a significant pediatric cancer.
• Methotrexate-based chemotherapy is a cornerstone in T-ALL treatment.
• Understanding treatment efficacy and prognostic factors is crucial for improving outcomes.

Purpose of the Study:

• To compare the efficacy of Capizzi methotrexate (C-MTX) versus high-dose methotrexate (HDMTX) in pediatric T-ALL.
• To evaluate the impact of central nervous system (CNS) involvement on treatment outcomes.
• To identify factors associated with relapse in T-ALL patients.

Main Methods:

• Retrospective analysis of 63 children diagnosed with T-ALL between 2001 and 2014.
• Comparison of patient outcomes based on C-MTX versus HDMTX regimens.
• Assessment of overall survival (OS) and disease-free survival (DFS) in relation to CNS status and treatment protocols.

Main Results:

• Complete remission (CR) achieved in 90% of patients.
• No significant difference in OS or DFS between C-MTX and HDMTX groups.
• Central nervous system stage 3 (CNS3) involvement was linked to significantly inferior OS and DFS.
• Delayed radiation in CNS3 patients correlated with increased relapse risk.

Conclusions:

• Both C-MTX and HDMTX are effective in achieving remission in pediatric T-ALL.
• CNS3 involvement represents a critical risk factor requiring intensified or optimized CNS-directed therapy.
• Further research is needed to optimize CNS prophylaxis and treatment strategies for T-ALL patients with CNS3 disease.